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1. Introduction
It is well established that adenosine 5P-triphos-
phate (ATP) plays the role of a universal ‘high en-
ergy’ compound. Under normal conditions ATP oc-
curs in cells at a concentration between 2 and 10
mmol/l [1]. The structure of ATP consists of three
kinds of building blocks. First, there is a heterocyclic
aromatic ring structure, adenine, which is a deriva-
tive of 6-aminopurine. Attached to the adenine base
through a glycosidic linkage is a molecule of the ¢ve-
carbon sugar, D-ribose, to which are attached, by
ester linkage, phosphate groups at the 5P-position.
The ATP molecule as it exists in the intact cell is
highly charged; at pH 7.0, each of three phosphate
groups is completely ionized. Thus ATP bears four
negative charges, which are concentrated around the
linear polyphosphate structure. This is an important
feature of the ATP molecule with respect to its ‘high
energy’ nature [2]. On the other hand, the structural
geometry of the ATP molecule is a matter of func-
tional importance because many enzymes that syn-
thesize and/or utilize ATP have active sites, of terti-
ary structure implicated by the so-called Walker
motifs A and B [3^6], to which the ATP structure
must ¢t exactly (Fig. 1).
The free energy of ATP hydrolysis (vG‡P 50 kJ/
mol) is signi¢cantly higher than that of simple esters,
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glycosides, and amides. It is also higher than that of
many phosphorylated compounds. The physiological
importance of ATP is related, however, to the fact
that it occupies an intermediate position on the ther-
modynamic scale of phosphate compounds [2]. The
function of ATP/ADP system is to act as an inter-
mediate ‘bridge’ or linking system between phos-
phate compounds having a high phosphate group
transfer potential, and other compounds having a
low phosphate group transfer potential, thus making
possible the transfer of phosphate groups from the
former to the latter. ADP serves as a speci¢c enzy-
matic acceptor of phosphate groups from cellular
phosphate compounds of very high potential. The
latter are formed during the energy-yielding oxida-
tion of foodstu¡s in the cell, and they conserve
much of the energy of the foodstu¡s. The ATP so
formed can now donate its terminal phosphate group
enzymatically to certain speci¢c phosphate acceptor
molecules, such as glucose or glycerol (which are
low-energy compounds), transforming them to their
phosphate derivatives and thus raising their energy
content [7].
The second important feature of ATP is not only
that is serves as a general energy carrier in all the
reactions in the cell which cause phosphorylation of
ADP to ATP at the expense of phosphate com-
pounds of very high potential, but also that all the
reactions by which the terminal phosphate group is
transferred to low-energy phosphate acceptors, are
catalyzed by enzymes. Furthermore, nearly all of
these enzymes are speci¢c for ATP and ADP, as their
active catalytic sites ¢t only ATP and ADP, and the
ATP/ADP system is the primary ‘main-line’ energy
carrier [1,2]. It is worth stressing, however, that ATP-
binding proteins comprise macromolecules di¡ering
in origin and molecular mechanism of interaction
with nucleotides, from ATP hydrolases, through var-
ious kinases (including protein kinases), other ATP-
utilizing enzymes, such as active transporters of me-
tabolites, endo- and xenobiotics (including multidrug
Fig. 1. A common nucleotide-binding domain in ATP/GTP-
binding proteins of various origin. The Walker A and B con-
sensus motifs are depicted. They consist of the following se-
quences: the Walker motif A is B-X4-Gly-X4-Gly-Lys-Thr-X5-
Leu (or Val), and the Walker motif B is Arg (or Lys)-X3-Gly-
X3-Leu-H4-Asp, where B stands for basic, H for hydrophobic,
and X for arbitrary (optional?) amino acid residue. Adenosine
5P-triphosphate and its interactions with magnesium ions, water
molecules and various amino acid residues are also shown. Oth-
er explanations are given in the text.
Fig. 2. Schematic illustration of functioning of ATP within the
cell, as an intracellular metabolic messenger and important
physiological ligand for many transport proteins, enzymes, reg-
ulatory and structural proteins. The inter-relationship between
ATP-generating systems and ATP-consuming processes, leading
to the changes in intracellular ATP concentration (some of
them leading to ATP depletion), is shown to underline the im-
portance of adenosine nucleotide homeostasis for cell function-
ing. The changes in ATP concentration are likely to be propa-
gated by various e¡ector proteins leading to speci¢c functional
responses.
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resistance or multidrug resistance-associated pro-
teins), to heat shock, contractile and motor proteins
[3,4,8].
ATP has a potent physiological impact in di¡erent
tissues by acting as an extracellular messenger (Fig.
2). Moreover, ATP and related nucleotides were
found to be potent Ca2 mobilizing agents and to
act intracellularly on both ionotropic (P2X) and met-
abotropic (P2Y) plasma membrane purinergic recep-
tors for extracellular nucleotides [9^11] that play im-
portant physiological and pathophysiological roles in
a variety of biological processes, such as neurotrans-
mission, contraction^relaxation cycle, secretion of
hormones, immune response, and cell growth. Mo-
lecular cloning of purinergic P2 receptors revealed
the molecular mechanism underlying the extra-
cellular action of ATP and other nucleotides [12].
P2Y receptors have seven transmembrane spanning
regions, are coupled to G-protein, and are involved
in inositol triphosphate (IP3) generation and Ca2
release from intracellular stores. P2X receptors are
coupled to ion channels related to Caenorhabditis
elegans degenerins and mammalian amiloride-
sensitive Na channels [13]. ATP released from pre-
synaptic terminals in a Ca2-dependent manner
may also play a role in long term potentiation
(LTP), a process that has been implicated in memory
formation [14]. ATP was also proposed as a cytosolic
factor involved in pain-sensing of tissue damage
[15].
In addition, over the past years, hundreds of ob-
servations concerning the direct intracellular e¡ects
of ATP on cellular functions have also accumulated.
Some of them could be interpreted to support the
action of ATP as a metabolic messenger. By the
term ‘metabolic messenger’ we understand a mole-
cule whose cellular concentrations re£ect the overall
metabolic activity of the cell [16]. The quantitative
changes in metabolic messenger concentration are
able to trigger various cellular events including insu-
lin secretion [17]. Moreover, it has been found that
cell respiration is controlled by ATP via an allosteric
inhibition of cytochrome c oxidase by the nucleotide
which binds to the matrix domain of subunit 1 of
this terminal enzyme of the mitochondrial respira-
tory chain [18]. In addition, the ATP level is pro-
posed to be an important determinant for cell death
since maintenance of the mitochondrial membrane
potential (v8), which is the driving force for mito-
chondrial ATP synthesis, prevents apoptosis [16].
ATP is able to interact with various enzymatic, reg-
ulatory and structural proteins, through its adenine
and ribosyl groups. In line with this property, it
has been discovered that many proteins are able to
bind ATP, but their binding is not accompanied by
ATP hydrolysis (e.g. ATP-sensitive K channels in
plasma [19] or mitochondrial [20,21] membranes or
ryanodine receptor/calcium release channel in sarco-
plasmic reticulum membranes of muscle cells [22,23]).
These observations pointed to the possibility of nu-
cleotides being functional ligands for many e¡ector
proteins within a cell (Fig. 2). In the interaction of
intracellular ATP with some proteins not involving
its hydrolysis, ATP acting as a small ligand or a
metabolic messenger, a¡ects directly the activity of
enzymes, channels and/or structural proteins [24].
Hence, modulation of the activity of the ATP-bind-
ing proteins by the nucleotide depends on two cellu-
lar factors.
First are activities of ATP-generating systems in
comparison to ATP-depletion processes. A high level
of ATP appears within the cell as a result of in-
creased activity of ATP-generating systems: due to
glycolytic and oxidative metabolism. It is known that
di¡erent substrates can contribute to ATP synthesis.
Glucose, lactate, free fatty acids and, to a lesser ex-
tent, ketone bodies and amino acids, can all be me-
tabolized to produce ATP [1,2]. ATP-depletion with-
in the cell is a result of complex events: of ATP
consuming processes such as gluconeogenesis, urea
synthesis, protein synthesis, activity of ATPases,
and as a result of conditions like ischemia or anoxia
followed by mitochondrial dysfunction in ischemia-
reperfusion [25]. Di¡erent metabolic processes con-
tribute in di¡erent ways to the ATP pool present in
cells, and it has been proposed that while cytoplas-
mic concentrations oscillate locally in cells, such os-
cillations may constitute important cell signals [24].
Hence, one can expect that di¡erent ATP-generating
processes will regulate to a varying extent the activity
of ATP-sensing enzymes. In fact, ATP generated
from glycolytic rather than from mitochondrial me-
tabolism is involved in glucose-stimulated insulin se-
cretion [26,27]. There are also observations suggest-
ing that activation of mitochondria directly triggers
the exocytosis of insulin in B-cells [28]. Probably in-
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sulin secretion is triggered by pleiotropic signaling
pathways [17,29^31]. Fatty acids are known to be a
primary source of ATP in the heart. There are also
lines of evidence that lactate may signi¢cantly con-
tribute to the production of ATP [32,33]. Addition-
ally, substrate preferences in the heart are modulated
by cardiac ischemia [34].
Second factor is a spatial distribution of ATP-gen-
erating systems within the cell, which parallelly with
the regulation due to increase or depletion of ATP,
maybe important. Glycolysis processes occurring in
cytosol and oxidative phosphorylation in mitochon-
dria cause compartmentation of ATP within the
cells, a¡ecting in this way the ATP-regulated proc-
esses [1,2]. In the heart, glycolytic enzymes may be
important in maintaining a high local cytosolic ATP/
ADP ratio in the vicinity of the ATP-regulated po-
tassium (KATP) channels [35,36].
In this review we would like to summarize recent
information about the interaction of intracellular
ATP with di¡erent proteins. Only interactions that
do not involve ATP hydrolysis will be taken into
account. In other words, the e¡ect of ATP as a lig-
and, but not as a phosphate group donor, will be
described. The article will focus on qualitative
changes of cell function due to quantitative changes
in cytosolic ATP content.
2. Targets for intracellular ATP
2.1. ATP-regulated ion channels
2.1.1. Plasma membrane KATP
Plasma membrane KATP channels, ¢rst discovered
in cardiac muscle [37], are inhibited by an increase of
the intracellular ATP concentration. They play an
important role in various cellular responses, such as
secretion and muscle excitability, by linking the cell
energetic status with the plasma membrane potential
[38]. The KATP channels are present in di¡erent cell
types such as cardiac, skeletal and smooth muscle
cells, pancreatic B-cells or neuronal cells [39]. In pan-
creatic B-cells the KATP channels are involved in in-
sulin secretion (Fig. 3). In the brain and in the heart
muscle under ischemia the level of ATP is lowered.
Decrease of ATP/ADP ratio would cause opening of
the KATP channels, resulting in shortening of the
duration of the action potential, preserving ATP
and hence serving a protective function during meta-
bolic stress. In smooth muscle cells the KATP chan-
nels participate in regulation of vascular tone [37^
39].
Recently two members of the inward recti¢er K
channel family were cloned, namely Kir6.1 and
Kir6.2 [40^42]. Together with the sulfonylurea recep-
tor (SUR), existing in three isoforms SUR1 and
SUR2A/B, they form a functional KATP channel.
Kir6.1 exhibits channel activity without SUR; nei-
ther Kir6.2 nor SUR1 exhibit full functional activity.
The SUR2A subunit and the Kir6.2 subunit can re-
constitute a KATP channel with properties similar to
those found in cardiac and skeletal muscles [43],
while the coexpression of Kir6.2 subunit and
SUR2B subunit reconstitute potassium channels
with similar properties to the smooth muscle cell
KATP channels [44]. Probably various SUR subunits
in combination with Kir6.x subunits contribute to
functional diversity of KATP channels [19]. The
KATP channels have weakly inward rectifying proper-
ties depending on magnesium or polyamines binding
to channel pore [45]. The studies on subunit stoichi-
ometry of the pancreatic B-cell KATP channels
(SUR1 and Kir6.2) indicate that the activity of
Fig. 3. The KATP channel functioning in pancreatic B-cells and
its connection with the secretion of insulin. The scheme repre-
sents a widely accepted mechanism of regulation of the KATP
channel activity, its close association with the overall cellular
energetic metabolism, and e¡ect on exocytotic release of the
hormone. The details of this mechanism are explained in the
text.
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KATP channels is the highest when subunits are coex-
pressed at a molar ratio of 1:1 [46,47]. Since inward
recti¢er potassium channels are functioning as tet-
ramers, this suggests that the KATP channel is active
as a multimeric protein, probably as an octamer
composed of a tetramer of the Kir6.2 subunit and
a tetramer of the SUR1 subunit [47]. Although two
di¡erent subunits, Kir6.2 and SUR1, are required for
formation of a functional KATP channel, recently it
was shown that removal of the last 26 amino acids of
Kir6.2 enabled channel activity and ATP inhibition
of the channel even in the absence of SUR1 [48]. It
seems that the site at which ATP (and ADP) mediate
channel inhibition lies on Kir6.2, whereas SUR1 con-
fers sensitivity to sulfonylureas, diazoxide (and prob-
ably other potassium channel openers), and potentia-
tion by MgADP [48]. Similarly to ADP, guanine
nucleotides have a dual e¡ect on the KATP channels:
at their concentrations exceeding 1 mM the channel
is blocked, while low concentrations (100 WM) stim-
ulate its activity [49]. Mutations in the SUR gene
appear to be the cause of abnormal insulin secretion
in persistent hyperinsulinemic hypoglycemia of in-
fancy (PHHI) [50].
The sulfonylureas such as glibenclamide or tolbut-
amide are insulin secretagogues widely used as oral
hypoglycemic agents in the treatment of diabetes
mellitus type II [51,52]. They were shown to inhibit
the activity of KATP channels [53,54]. Molecular
cloning of the high a⁄nity SUR [55] has revealed
that it is a member of the ATP-binding cassette
(ABC) superfamily of proteins [56,57] and has two
nucleotide-binding sites that contain Walker A and B
consensus motifs [3]. In other ABC transporters these
motifs are involved in binding and hydrolysis of
ATP. Two residues are of particular importance:
an aspartate residue within the Walker B motif co-
ordinates the magnesium ion of MgATP, while a
lysine in Walker A motif is critical for ATP hydrol-
ysis. In SUR1 these residues are indispensable for
MgADP to be able to activate the KATP channel
activity [58,59]. In addition to ADP, low concentra-
tion of guanine nucleotides GTP, GTPQS, GDPQS
and GDP activate the KATP channels in B-cells
[49]. As in the case with ADP, this e¡ect of guanine
nucleotides requires the presence of magnesium ions.
The stimulatory e¡ect of both GTP and GDP was
explained by direct interaction of the guanine nucleo-
tides with the KATP channel and interaction with
GTP-binding proteins. Recently it was shown that
GTP blocks the KATP channel by direct interaction
with Kir6.2 and the stimulatory e¡ect of GTP is
mediated by SUR1 [60]. Moreover, it was shown
that potentiating e¡ects of GTP and GDP on the
KATP channel and their ability to enhance diazoxide
stimulation are e¡ected via SUR1 [60]. It is believed
that Walker motifs play an essential role in KATP
channel activation by MgADP and potassium chan-
nel opener diazoxide [61]. The interaction of sulfo-
nylureas with SUR1 abolishes the stimulatory action
of MgADP [59].
The KATP channels have been characterized mostly
in pancreatic B-cells where they play the role of a
cytosolic ATP sensor triggering the exocytosis of
insulin [62,63]. In pancreatic B-cells the KATP chan-
nel regulates insulin secretion in response to eleva-
tion in glucose content which is its primary physio-
logical stimulus. The consensus view concerning
B-cell stimulus^secretion coupling is that when plas-
ma glucose levels rise, glucose uptake and metab-
olism by the pancreatic cell is increased. The result-
ing increase in intracellular ATP, and concomitant
lowering of intracellular MgADP result in the clo-
sure of the KATP channels followed by plasma mem-
brane depolarization. This activates voltage-depend-
ent calcium channels, increases calcium in£ux into
the cell and triggers insulin release. Mitochondria
are thought to play a central role in the generation
of the signal that couples glucose metabolism to in-
sulin secretion in pancreatic B-cells [64,65]. It was
shown that probably also factors other than calcium
and ATP and generated by mitochondrial metab-
olism are capable of inducing insulin exocytosis
[28].
The KATP channels also interact with drugs known
as potassium channel openers [66]. In contrast to
sulfonylureas, the potassium channel openers, such
as diazoxide, activate KATP channels thereby hyper-
polarizing the B-cell and inhibiting insulin release. In
pancreatic B-cells insulin secretion is an oscillating
process, due to metabolic and ATP/ADP level oscil-
lation leading to opening and closing of ATP-sensi-
tive channels [67]. Interestingly, it was also observed
that metabolic oscillations in heart cells caused oscil-
lations of the ATP-regulated membrane current
[68,69].
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2.1.2. KATP channel in mitochondria
The ion channel highly selective for K present in
the inner membrane of rat liver mitochondria [70]
(Fig. 4), is blocked by ATP and by the antidiabetic
sulfonylurea derivative, glibenclamide [70,71]. Re-
constitution of the partially puri¢ed mitochondrial
KATP (mitoKATP) channel into planar phospholipid
membranes (‘black’ lipid membranes) was also per-
formed and enabled to estimate at 30 pS the single
channel conductance at saturating K concentration
[71]. Recently, results have been shown suggesting
that Kir6.1 might be a subunit of the ATP-sensitive
potassium channel in the mitochondrion, as well as
in the plasma membrane [72].
The mitoKATP channel is reversibly inactivated by
ATP [70], its activity being half inhibited at 0.8 mM
ATP and almost completely blocked at s 2 mM.
Further studies on inhibition by ATP of the
mitoKATP channel were performed after partial puri-
¢cation and reconstitution of the channel into phos-
pholipid liposomes [71], and a strong inhibitory e¡ect
of ATP on K transport, was observed (K1=2 22^30
WM). Mg2 was required to obtain inhibition by
ATP, but neither ATP nor Mg2 alone was e¡ective.
In contrast, in intact mitochondria potassium trans-
port was inhibited by Mg2 alone. It is not clear why
inhibition of the mitoKATP channel by ADP was
observed after its reconstitution into proteoliposomes
[71], but not in patch-clamp studies on mitoplasts
[70].
It has been shown that guanine nucleotides reverse
the inhibition of mitoKATP channel by ATP and
ADP [73]. GTP and GDP are fully able to activate
the channel in the presence of 500 WM ATP with a
Ka of 7 and 140 WM, respectively. It has been pro-
posed that the endogenous activators (GTP or GDP)
overcome the high a⁄nity binding for ATP and play
a role of physiological regulators of the mitoKATP
channel [73]. An important point concerns the orien-
tation of the mitoKATP channel in the inner mito-
chondrial membrane. According to Garlid and his
co-workers [73,74], the regulatory sites for ATP
and GTP face the intramembrane space. There are
also some observations suggesting that the ATP
binding site faces the matrix compartment [70].
This problem, important for understanding of func-
tioning of mitoKATP channels within the cells, needs
further clari¢cation. The data on unidirectional K
transport in mitochondria come from studies on in-
tact (isolated) mitochondria. It is well known that
respiring mitochondria exhibit electrophoretic K
uptake, the process known as K uniport [75]. In
studies on modulation of the activity of this uniport
by adenine nucleotides it was demonstrated that K
in£ux was inhibited by adenine nucleotides with IC50
values of 0.5 and 2.3 WM for ADP and ATP, respec-
tively [76]. K transport was also inhibited by AMP
and by a nucleotide analog belonging to the triazine
dye family, Cibacron blue F3GA [76]. It was con-
cluded that the mitoKATP channel was, at least par-
tially, involved in the K uniport activity [76]. It has
been also shown that the K uniport induced by
magnesium depletion is inhibited by glibenclamide
in a concentration-dependent manner [20,77]. Also
other antidiabetic sulfonylureas are able to block
the K uniport induced in this way [20,78]. In fact,
in intact rat liver mitochondria only a single class of
low-a⁄nity binding sites for glibenclamide, with Kd
of 4 WM, was found [21]. In beef heart mitochondria
Kd for glibenclamide binding is by one order of mag-
nitude lower, e.g. 300 nM, than that in rat liver mi-
tochondria [21].
Similarities in the properties of plasma membrane
KATP channels and mitoKATP channels concern also
their interaction with non-sulfonylurea inhibitors (for
review see [20]). It has been shown that a guanidine
Fig. 4. Interaction of mitochondrial KATP channel with various
e¡ectors, such as ATP/GTP nucleotides, antidiabetic sulfonylu-
reas, and potassium channel openers. This scheme shows a
putative role of the mitoKATP channel and K/H exchanger in
potassium ions and protons tra⁄c in mitochondria. MitoSUR
represents the mitochondrial sulfonylurea receptor.
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derivative, U-37883A, acts as a vascular KATP chan-
nel antagonist [79]. This compound was also shown
to inhibit the K in£ux into rat liver mitochondria
[80], thus suggesting that it is active against the
mitoKATP channel as well. The mitoKATP channel
is blocked also by quinidine [81].
Plasma membrane KATP channels are speci¢cally
activated by such drugs as diazoxide, pinacidil and
minoxidil sulfate, known as potassium channel open-
ers (for review see [82]). It has been found that the
potassium channel opener, RP66471, induces a de-
crease of the mitochondrial membrane potential
[83]. Recently, other potassium channel openers
were shown to activate potassium transport in mito-
chondria. ATP-inhibited K £ux was restored by
diazoxide (K1=2 0.4 WM), cromakalim (K1=2 1 WM)
and two cromakalim analogs, EMD60480 and
EMD57970 (K1=2 6 nM) [84].
Physiological functions of mitoKATP channels are
not clear because of confusing phenomena involved
in the regulation of this channel. In view of the phys-
iological concentration of ATP the mitoKATP chan-
nel should be closed constantly. Only a dramatic
lowering of the ATP level should activate the channel
and this would lead only to membrane depolariza-
tion followed by permanent inhibition of mitochon-
drial metabolic activity. It may be speculated that, in
spite of the fact that ATP inhibits the mitoKATP
channel activity, ‘ATP depletion’ is not the only
physiological process leading to channel activation.
Probably other e¡ectors, like GTP and GDP or some
proteins, are involved in ¢ne regulation of the
mitoKATP channel activity [73].
Taking into consideration all that is mentioned
above, the mitoKATP channel may have a dual phys-
iological function. Firstly, a concerted action of the
electrophoretic K uniport and the electroneutral
K/H exchange is believed to be the main mecha-
nism responsible for maintaining potassium homeo-
stasis within the mitochondrion, and thus for con-
trolling intramitochondrial osmolality and volume
of mitochondria. Regulatory changes of this volume
are regarded as one of the important mechanisms of
metabolic control at the mitochondrial level (for re-
view see [85]). Observations that glibenclamide and
ATP inhibit mitochondrial swelling whereas KATP
openers potentiate the swelling make it likely that
this channel, perhaps together with other potassium
pathways, is involved in regulatory changes of mito-
chondrial volume [85].
Secondly, energization of mitochondria is accom-
panied by a net uptake of K, which is simultane-
ously inhibited by glibenclamide and activated by the
well known openers of the plasma membrane potas-
sium channel. This is compatible with the hypothesis
that potassium uptake upon energization partly com-
pensates for the electric charge transfer produced by
the proton pump and thus enables the formation of
vpH along with v8. This was further substantiated
by the observation that the rate of vpH formation
increases with increasing K concentration in the
external medium and thus with increasing rate of
K in£ux [86]. The ¢nal steady-state value of vpH
also increases whereas that of v8 decreases at in-
creasing K concentration so that the resulting pro-
tonmotive force remains practically unchanged. The
assumption that K transport accounts for the for-
mation of vpH is also supported by the observation
that both the rate of vpH formation and its steady-
state level in energized mitochondria are increased by
the potent opener of KATP channel, RP66471 [86]. As
shown previously [83], this compound decreases v8
of energized liver mitochondria by increasing the per-
meability of the inner mitochondrial membrane to
K. All this would also suggest possible involvement
of the mitochondrial KATP channel in regulation of
processes driven by the mitochondrial transmem-
brane potential, e.g. adenine nucleotide transport or
calcium uptake, and by vpH, e.g. phosphate and
pyruvate transport.
2.1.3. ATP-regulated potassium channel in zymogen
granules
An activity similar to that in the mitoKATP chan-
nel was found in isolated pancreatic zymogen gran-
ules in an assay measuring bulk cation in£ux driven
by a proton di¡usion potential [87]. Conductance
was decreased by monovalent cations in the follow-
ing order: Rb s K s Na s Cs s Li. Over
50% of the K conductance was inhibited by milli-
molar concentrations of ATP or MgATP. The inhib-
ition by MgATP, but not by ATP itself, was reversed
by the K channel opener, diazoxide. The inhibitory
e¡ect of nucleotides was probably due to non-cova-
lent interactions, as these can be mimicked by non-
hydrolyzable analog of ATP and by ADP. The re-
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versal of MgATP inhibition by diazoxide may be
mediated by phosphorylation as it is blocked by
the protein kinase inhibitor, H7. Sensitivity to anti-
diabetic sulfonylureas, such as glibenclamide and tol-
butamide, is also observed. The transport of K by
granules was also measured indirectly by ionophore-
induced lysis of the isolated secretory granules sus-
pended in a KCl-containing solution [88]. ATP at a
physiological level inhibited the K transport in a
dose-dependent manner, but ADP did not reverse
the inhibition. The antidiabetic sulfonylurea, tolbut-
amide (0.5 mM), also reduced ionophore-dependent
granular lysis by 46%. The ATP sensitivity of K
transport was in£uenced by pH (increased ATP sen-
sitivity with decreasing pH). Preincubation with
phospholipase A2 or lysophospholipids produced a
signi¢cant decrease, through an unknown mecha-
nism, in the granule K transport. The possible
role of granule-associated K transport in pancreatic
ascinar cells could be a contribution to granule swell-
ing as a step preceding membrane fusion during
exocytosis [88].
2.1.4. Ryanodine receptor
Ryanodine receptors are a family of intracellular
Ca2 release channels that were originally identi¢ed
in the sarcoplasmic reticulum membranes of skeletal
muscle cells. In mammalian tissues three members of
this family have been identi¢ed so far, the skeletal
muscle (RyR1), the cardiac muscle (RyR2), and the
brain (RyR3) ryanodine receptors. These proteins are
products of di¡erent genes and share 66^70% amino
acid sequence identity [89^93]. Previously these re-
ceptors were thought to be di¡erently expressed,
with RyR1 predominantly expressed in skeletal
muscle cells, RyR2 mainly expressed in heart, but
also in brain, and RyR3 in certain regions of brain,
and in smooth muscle cells. Recently, they were
found to be widely expressed, most of the tissues
expressing more than one RyR isoform [94,95].
RyR1 and RyR2 function as Ca2 release channels
from the sarcoplasmic reticulum intracellular calcium
store and play a crucial role in the excitation^
contraction cycle of skeletal muscles [90,92,96^98].
Both these channels have been puri¢ed, reconstituted
[99] and characterized. Structurally each is a homo-
tetramer of molecular weight of 4U564 kDa
[100,101] with tightly associated four molecules of
immunophilin of molecular weight of 12 kDa (im-
munosuppressant drug FK506-binding protein ^
FKBP12) with cis^trans peptidyl-prolyl isomerase ac-
tivity [102^105]. Genes encoding both isoforms have
been cloned and products of their expression re-
vealed 66% identity [106]. FKBP12, which can be
removed from RyR by incubation of skeletal muscle
terminal cisternae membranes with an immunosup-
Fig. 5. The interaction of the ryanodine receptor (RyR)/calcium release channel of sarco(endo)plasmic reticulum membranes with cal-
cium ions, various physiological ligands and some drugs. The RyR homoterotetramer is schematically shown; the activation of the
channel is marked (+), inhibition with (3), and mixed e¡ects with (+/3). FKBP12 stands for immunorepressant FK506-binding pro-
tein of 12 kDa.
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pressive drug, rapamycin, seems to coordinate the
gating of channel activity in both control and ryano-
dine-modi¢ed RyR [105] and to reduce the frequency
of channel subconductance states [103].
RyR isoforms di¡er, however, from each other in
their sensitivity to various e¡ectors and to plant al-
kaloid, ryanodine [100,107] (Fig. 5). Binding of rya-
nodine to puri¢ed and membrane-bound RyR has
been found to be modulated by propranolol, a B-
blocker [108]. When incorporated into lipid bilayers
puri¢ed RyR forms a large conductance channel per-
meable to monovalent and divalent cations, which
can be activated by submicromolar amounts of
Ca2, ATP, and ca¡eine, and inhibited by millimolar
amounts of Ca2, Mg2, and Ruthenium red
[22,109^111]. RyR isoforms are activated also by
ADP-ribose, cADP-ribose, L-NAD [23] and suramin
[112]. However, di¡erences in their response to cyclic
ADP-ribose [113,114] as well as to inorganic phos-
phate and perchlorate [115] have been reported. Age-
related abnormalities in their regulation has been
also observed [116]. Interestingly, nitric oxide, the
endothelial-derived relaxing factor, which is known
to depress force in smooth and cardiac muscles
through the action of guanylyl cyclase and an in-
crease in cGMP, increased the open probability of
RyR and inhibited ryanodine binding to RyR.
Ca2 release through RyR was induced by nitric ox-
ide free radicals, and was potentiated by cysteine
involving formation of nitrosylated cysteine in the
presence of O2, followed by transnitrosation of reg-
ulatory thiols on RyR and activation of the channel
[117]. Most of the RyR1 and RyR2 ligands interact
with the channel domains exposed on the cytoplas-
mic side of sarcoplasmic reticulum membranes
[23,118], as depicted on Fig. 5. There is, however,
one exception, that of annexin VI. Annexin VI has
been shown, using the patch-clamp technique, to
modulate in in vitro experiments RyR1 by increasing
2.7-fold open probability of the channel and by
82-fold the mean open time [119^121], and to inter-
act with the domain of the channel exposed to the
lumen of sarcoplasmic reticulum membrane [119]. It
should be mentioned, however, that the latter func-
tion of annexin, due to its ability to form Ca2 chan-
nels in liposomes [122] has been recently questioned
[123].
RyR1 and RyR2 bind Ca2 and calmodulin and
become phosphorylated by various protein kinases
including Ca2/calmodulin- and cAMP-dependent
kinases [124^126]. Phosphorylation of RyR2 by
cAMP-dependent kinase activates the channel [127],
while that of RyR1, inhibits Ca2 release [128]. In
addition, it has been demonstrated that skeletal
muscle RyR is modulated by endogenous phosphor-
ylation of 160/150 kDa proteins of sarcoplasmic re-
ticulum membrane [129], and the kinase involved has
been identi¢ed [130]. Calmodulin, after binding to
RyR1 and RyR2, inhibits transport activity of the
channel and decreases the probability of channel
opening [23,131]. ATP activates calcium release
from sarcoplasmic reticulum cisternae of skeletal
and heart muscles; in the presence of physiological
concentrations of ATP the probability of channel
opening is increased [118,132,133]. RyR2 is also ac-
tivated by adenosine and its analogs [134]. In RyR1
and RyR2 a domain near Arg615 is responsible for
the binding of ATP and the same region has been
found in the receptor of IP3 [135].
In the case of RyR3 there is still but a limited
number of observations available. Isolation and bio-
chemical characterization of RyR3 have been im-
peded by its low abundance and its coexpression
with other RyR isoforms. Signi¢cant progress in
understanding the function and regulation of RyR3
has been made due to generation of mice with a null
mutation in the RyR1 gene [136]. Recently, the
RyR3 cDNA from rabbit uterus was cloned and ex-
pressed in HEK293 cells. Recombinant RyR3 was
activated by 100 nM Ca2 and inactivated at
10 mM Ca2. Calmodulin activated the channel at
low Ca2, and inhibited at high Ca2 concentration.
The cloned RyR3 was activated by ATP, ca¡eine,
and perchlorate, inhibited by Mg2 and Ruthenium
red, and modi¢ed by ryanodine; cADP-ribose, how-
ever, was without e¡ect [137]. The cloned RyR3 was
found to di¡er from RyR1 in the gating behavior,
the extent of maximal activation by Ca2, and sensi-
tivity to Ca2 inactivation [137].
It has also been found that the activity of a class
of intracellular Ca2 release channels, IP3 receptors,
distinct from RyR, is also modulated by ATP. IP3
receptors are found in all types of cells. They are
homotetramers of molecular weight of 4U315 kDa
[106,118,138]. Two domains exposed on the cytoplas-
mic side of endoplasmic reticulum are involved in
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binding of second messengers, which is followed by
channel opening [138]. IP3 receptors are encoded by
four genes, resulting in expression of various IP3
receptor isoforms [138]. These receptors are also
regulated by phosphorylation catalyzed by protein
kinase C and cAMP- or/and Ca2/calmodulin-de-
pendent protein kinases [139^141], or, alternatively,
undergo autophosphorylation [142]. Calcium ions act
on both cytoplasmic and luminal portions of the re-
ceptor. ATP has been found to interact with two
domains within the receptor molecule, localized on
the cytoplasmic side of the membrane, which are
responsible for the transmission of conformational
changes occurring in the protein molecule upon bind-
ing of IP3. Binding of ATP was e¡ective at nucleo-
tide concentrations lower than physiological ones
[140,143,144]. This may suggest the involvement of
Ca2-ATPase which may locally reduce ATP concen-
trations by its hydrolysis [140], ATP was found to act
on IP3 receptor biphasically; in the presence of ATP
at concentrations below 2 mM the channel is acti-
vated, and above 4 mM it becomes inhibited [22].
The inhibition of IP3-induced Ca2 release by caf-
feine in permeabilized A7r5 cells is prevented by
ATP and MgATP (5 mM), suggesting that ca¡eine
may interact with an ATP-binding site on the IP3
receptor or, may be, with other receptor-associated
proteins [145].
2.1.5. ATP-regulated cardiac Ca2+ channel
It is known that calcium current in cardiac myo-
cytes is dependent on metabolic status of the cells,
and is regulated by protein kinase A [146]. Therefore,
the e¡ect of ATP on calcium current has been attrib-
uted mainly to stimulation of protein phosphoryla-
tion. ATP was found to promote channel activity by
preventing its Ca2-mediated inactivation [147,148]
or Ca2-activated proteolysis [148,149]. Interestingly,
calcium current was enhanced not only by MgATP,
but also by a non-hydrolysable ATP analog [150].
Recently, the possible role of ATP in regulation of
L-type channel was investigated in guinea pig ven-
tricular cells [151] and a stimulatory action of
MgATP in inside-out patches was observed. Similar
e¡ects were also noticed in the presence of 5P-adenyl-
ylimidophosphate (AMP-PNP), a non-hydrolysable
ATP analog, suggesting that hydrolysis of ATP is
not required for the stimulatory e¡ect of the nucleo-
tide on channel activity. In addition, a protein kinase
inhibitor H8 did not abolish the e¡ect of MgATP,
suggesting that a phosphorylation event is not in-
volved in regulation of channel activity [151].
2.1.6. ATP-dependent anion channels
Transcellular Cl3 £uxes play a pivotal role in the
control of salt and £uid secretion, pH balance, os-
moregulation, cardiac function, and volume-depend-
ent metabolic e¡ects. The physiological importance
of Cl3 transport is re£ected by the diversity of Cl3
channels that are expressed in eukaryotic cells, and
the numerous intracellular signaling pathways in-
volving Ca2, cAMP and ATP, that regulate them
[152,153].
Recently, an anion channel from rat brain synaptic
plasma membrane has been incorporated into planar
lipid bilayers and was found to exhibit low anion
selectivity to Cl3. The channel was not regulated
by changes in membrane potential. Several drugs,
e⁄cient inhibitors of anion channels, such as 4-ace-
toamino-4P-isothiocyanostilbene-2,2P-disulfonic acid,
ethacrynic acid, indanyloxyacetic acid, and 5-nitro-
2-(3-phenylpropylamino)benzoic acid, inhibited the
channel from the cytoplasmic side of plasma mem-
brane. This channel was found to be regulated by
intracellular ATP at millimolar concentrations, as
well as by other nucleotides, ADP and GTP, which
inhibited its activity [154]. In addition, the channel
was inhibited by glibenclamide when present at mi-
cromolar concentrations, from the extracytoplasmic
side of the membrane [154].
Another type of ATP-regulated chloride conduc-
tance exists in endoplasmic reticulum-enriched pan-
creatic microsomes [155]. Chloride conductance in
these microsomes was inhibited by stilbene
(0.1 mM) and indanyloxyacetic acid (10 WM) deriv-
atives. ATP stimulated the conductance with half-
maximal stimulation at 8 WM. Other trinucleotides
when used at concentrations not exceeding 100 WM
were without e¡ect. The non-hydrolysable ATP ana-
log had the same e¡ect as ATP, while ATPQS, which
is a substrate for kinases, was without e¡ect [155].
ATP stimulation was reversed by stilbene derivatives.
In addition, evidence has been presented that this
channel is not immunologically identical with a cystic
¢brosis transmembrane conductance regulator, but
rather represents a novel type of chloride channel
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which is regulated by ATP. ATP, in this case, does
not need to be hydrolyzed and its spatial conforma-
tion is important for activating Cl3 conductance
[155].
2.2. Annexins
2.2.1. Basic characteristics of annexins
Annexins form a family of multifunctional ubiqui-
tous intra- and extracellular calcium- and phospho-
lipid-binding proteins (up to 1^2% of total protein
content), that are able to interact with membranes in
a calcium-dependent manner. Although their in vivo
functions remain unsolved, on the basis of the results
of numerous in vitro experiments annexins have been
frequently suggested to serve as connecting elements
between plasma membrane and intracellular compo-
nents, such as cytoskeleton (F-actin, spectrin), endo-
somes, lysosomes, and other vesicular structures
[123,156^160]. So far ten di¡erent subfamilies in
man and many more genus and tissue speci¢c sub-
families and isoforms have been described [123,156^
158,161]. In contrast to the superfamily of Ca2-
binding proteins (e.g. calmodulin and troponin C),
which are able to mediate various cellular processes
in response to changes in Ca2 concentration over
the range from 0.1 to 1 WM [162], annexins lack
the calcium-binding sites of the ‘EF-hand’ structure
[161^165]. On the other hand, they have speci¢c re-
peatable motifs, called the ‘annexin folds’, which rep-
resent a second to the C2 domain of protein kinase
C, phospholipase C, synaptotagmin, phospholipase
A2, rabphillin, copines, and many other proteins,
the major protein motif that regulate calcium-de-
pendent interactions with membrane lipids [166^
168]. The annexin fold is similar, with some respect
to tertiary structure and mechanism of Ca2 binding,
to calcium-binding sites (type II) of cytosolic 85-kDa
phospholipase A2 [168,169]. The analysis of tertiary
structure of annexins revealed the existence in these
proteins of specialized phospholipid-binding sites ex-
hibiting speci¢city for certain phospholipid classes
[161^165]. Two major regions can be distinguished
within an annexin molecule: a conserved core region
comprising four (in human annexins I^V, VII, VIII,
XI and XIII), or eight (only in annexin VI), repeated
amino acid sequences, and a variable, di¡ering in
length, regulatory N-terminal region. The core region
is the site of a calcium and phospholipid binding to
an annexin molecule as evidenced by combinatory
mutagenesis [170] or crystal structure analysis
[122,171,172], while the terminal N-region contains
sequences which are phosphorylated in di¡erent an-
nexins by distinct protein kinases [156,157]. Simulta-
neously these sequences form sites of interaction with
various proteins, such as S-100 [123], F-actin [123],
pro¢lin [173], tissue plasminogen activator (t-PA)
[174,175], apolipoprotein A1 [176], p120GAP (an acti-
vator of GTPase p21ras) [177], and ion transporters
including RyR [119^121], and the Ca2-dependent
chloride channel from epithelial cells [178,179]. An-
nexins bind also extracellular matrix proteins, e.g.
collagen [180] and tenascin-C [181]. They exhibit
lower a⁄nity to Ca2 than the ‘EF-hand’ calcium-
binding proteins and, therefore, seem to be less sen-
sitive to changes in intracellular calcium concentra-
tion. In fact, some of the annexin isoforms were
found to bind to membranes in a calcium-independ-
ent mode [182^186], and in case of annexin II^early
endosomes interactions it has been proposed that
these interactions could be mediated through speci¢c
membrane receptors [187].
On the basis of numerous in vitro observations
annexins have been implicated in calcium signal
transduction in certain cells and calcium homeosta-
sis. First, the expression of annexins, although con-
secutive, is frequently tissue-restricted and cell-specif-
ic [156]. Genes encoding some annexins are
speci¢cally regulated, e.g. by prolactin [156], proges-
terone [188], glucocorticoids [156], retinoids [189] and
thyroid hormones [190], and are often related to the
processes of cell di¡erentiation and proliferation.
Moreover, a promoter for binding of an early re-
sponse gene product, AP1, has been identi¢ed up-
stream of the annexin V-encoding gene [191], and
annexins V and II are encoded by fos-induced genes
[192]. Second, an important role in annexin function-
ing is played by phosphorylation, catalyzed by vari-
ous tyrosine and serine/threonine protein kinases
which participate in transduction of mitogenic signal
[193^195]. In turn, annexins were found to be inhib-
itors of several protein kinases, inhibition of these
kinases resulting in changes in permeability of mem-
branes to ions [194] or in modulation of cellular re-
sponses to insulin [196]. Third, annexins undergo
translocation from cytoplasm to plasma membranes
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and phagosomes in response to changes of cytosolic
[197^201] or nuclear [202] Ca2 concentrations upon
cell stimulation.
Annexins are believed able to perform these func-
tions because almost all them examined to date can
form in vitro voltage-dependent ion channels
[123,156,157,203,204]. Some of annexins exhibit se-
lectivity towards Ca2, as shown for example for
annexin V. Annexin V which in the pore region of
the channel contains Glu128, Glu129, Glu130 and
Asp137 residues, and is acidic, is therefore, expected
to be cation-selective [205]. In the case of annexin
XII hexamer, the side chains of Lys132, Lys128 and
Lys137 from each of the six monomers provide the
region immediately adjacent to the mouth of the pore
with a basic environment, expected to reveal selectiv-
ity towards anions [206]. In connection with their
channel activity, annexins were also implicated in
endo- and exocytosis [207], since they are able to
modulate membrane aggregation and fusion in a cal-
cium-dependent manner [207^210]. These processes
are prerequisite for secretion of hormones and neuro-
transmitters, and for bile formation [211]. In addi-
tion, annexins are involved in regulation, as non-spe-
ci¢c inhibitors, of phospholipase A2 activity
[156,158]. Some annexins bind heparin [212,213], sig-
naling molecules and neurotransmitters or their pre-
cursors, e.g. choline [176,213].
By the mode of interaction with membranes an-
nexins resemble protein kinase C isoforms [214], as
well as 85-kDa cytosolic phospholipase A2 [215], and
even calpains, cytosolic proteases active at the mem-
branes [216]. Like protein kinase C and phospholip-
ase A2, annexin isoforms alternate within a cell be-
tween two major states: soluble, at relatively low
Ca2 concentrations in cytosol, and membrane-
bound, at higher Ca2 concentrations, mainly asso-
ciated with the cytoplasmic lea£et of plasma mem-
brane by two distinct mechanisms: one reversible
and Ca2-dependent, and another requiring Ca2 in-
itially but subsequently Ca2-independent [123]. An-
nexins were also isolated in association with endo-
plasmic (sarcoplasmic) reticulum membranes
[182,217] and with mitochondria [218,219].
2.2.2. Interaction of some annexin isoforms with
nucleotides
In the light of existing binding data and dissocia-
tion constants of annexins for calcium, it is di⁄cult
to explain their cellular localization since even in
stimulated cells free Ca2 levels are rarely in the mi-
cromolar range. Moreover, various annexin isoforms
were found to bind to the membranes even when
intracellular Ca2 concentrations reached low resting
levels. In fact, it has been observed that relocation of
annexin V to platelet membranes upon cell stimula-
tion is a phosphorylation-dependent process, as
shown by using the protein kinase inhibitor, stauro-
sporine, and immunoprecipitation [220]. In bovine
heart, lungs and brain some annexins partitioned in
the micellar phase after non-ionic detergent treat-
ment [182,184]. On the other hand, it has been also
observed that a Ca2-dependent binding of annexin
VI to membranes is resistant to treatment with de-
tergents and, in addition, annexin VI was found to
colocalize with actin binding proteins, K-actinin and
¢mbrin. This suggests that annexin may interact also
with cytoskeleton [221] or other speci¢c membrane
receptor [187]. Interestingly, it has been reported that
ATP at the physiological concentration range poten-
tiates association of annexin VI with the hepatocyte
plasma membrane, especially at submillimolar con-
centrations of Ca2 [222]. This particular observation
may indicate that not only binding of Ca2 to the
protein molecule, but also other ligands, nucleotides,
may in£uence the interaction of annexins with mem-
branes.
In fact, some annexins have been shown to interact
in vitro with nucleotides [223^225] and biochemical
and functional evidence has been provided that they
may belong to a superfamily of ATP-binding pro-
teins of various origin. However, one has to remem-
ber that structure of annexins does not contain the
Walker consensus motifs A and B characteristic of
ATP/GTP-binding proteins [3,6]. Speci¢cally, ATP
and cAMP were found to bind in vitro to bovine
lung annexin I in£uencing its ability to aggregate
liposomes and chroma⁄n granules, and to form cal-
cium channels [223,226]. Annexin VI was successfully
puri¢ed by a⁄nity chromatography on ATP-agarose
[227]. By comparing primary structures of annexins,
cystic ¢brosis transmembrane conductance regulator
and various cAMP-binding proteins it has been dem-
onstrated that annexins share some homology with
cyclic nucleotide-binding proteins [223,228]. The
strongest arguments came from in vitro observations
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that annexin VI of porcine liver is an ATP-binding
protein [224,225], which suggests that a nucleotide-
binding domain may exist within the annexin VI
molecule exhibiting structural features di¡erent
from those found in other ATP-binding proteins
[225,229]. The nucleotide-binding domain of annexin
VI is probably localized in a hydrophobic pocket
between two symmetric lobes of the protein mole-
cule, each consisting of four Ca2- and phospho-
lipid-binding domains [225], in analogy to the hydro-
phobic pocket within the actin molecule [230], and
other related proteins [7,230^233]. The connector be-
tween these lobes may participate in creation of an
ATP-binding domain of the protein, since in most of
annexin VI genus-speci¢c isoforms it contains a
unique Trp343 residue [122]. These speculations are
strengthened by indirect evidence that the binding
of ATP to annexin VI implies a rearrangement with-
in the protein molecule tertiary structure leading to
change in exposure of the Trp343-containing domain
[225] and also by observation made for other ATP-
binding proteins revealing the importance of partic-
ular tryptophan residue in stabilization of adenine
ring of nucleotide while bound to the ATP-binding
pocket of protein [234,235].
As it was already mentioned, the large eight-
domain annexin VI is able to bind e⁄ciently and
speci¢cally ATP with high a⁄nity, KdW5 WM
[224,225]. ATP and other adenine nucleotides quench
the intrinsic £uorescence of annexin VI which, in
the case of trinitrophenyl-ATP, is accompanied by
a £uorescence energy-transfer between protein
tryptophan residues and the nucleotide [225]. ATP
binding to annexin VI changes its in vitro inter-
action with arti¢cial and biological membranes,
and with the cytoskeleton [224], but such an e¡ect
of has not been observed in the case of annexin IV
[236].
In the next chapter we will focus on two possibil-
ities. First, annexins may react to the local changes in
intracellular ATP concentrations which is an addi-
tional signal to calcium, resulting in changes of the
interaction of annexins with membrane components.
As an alternative possibility, annexins bind ATP, this
in£uencing their conformation and function; the nu-
cleotide signal is then stopped by dissociation regu-
lated, e.g. by calcium, after which annexins return to
the resting state.
2.2.3. The e¡ect of nucleotide binding on annexin
functioning
Annexins, by interacting with membranes and cy-
toskeleton, may participate in vesicular transport and
membrane tra⁄cking; in these processes, in addition
to calcium ions, ATP plays a crucial role [123,237]. It
has been reported that fusion among endosomes is
an important step for transport and sorting of inter-
nalized macromolecules and, in the absence of Ca2,
requires ATP and cytosol. Evidence has been pre-
sented that annexin II and arachidonic acid are in-
volved in a calcium-dependent fusion event [208],
however, no observations have been published yet
that annexin II is an ATP-binding protein.
Annexins may act as e¡ectors of the nucleotide
signaling pathway within the cell, and changes in
nucleotide concentration, especially under metabolic
or oxidative stress, may engage annexins as e¡ectors
and mediators of various intracellular reactions in-
volved in calcium-mediated signaling and energy
transduction. The initial stage in the process of con-
verting a calcium signal into a change in cellular
function is binding of calcium to an appropriate cal-
cium-binding protein. Most cells contain many such
proteins, among them calmodulin, protein kinase C,
calcium-dependent proteases (calpains), and cyto-
skeleton-associated proteins, particularly those in-
volved in the regulation of actin ¢laments, one of
the best-known examples being gelsolin, an ATP-
binding protein exhibiting low a⁄nity for the nucleo-
tide [227,238]. Some of them like synapsins I and II,
abundant components of synaptic vesicles, were
found to bind ATP with high a⁄nity through a sin-
gle, evolutionarily conserved glutamate or lysine res-
idues, respectively, and the binding of ATP to syn-
apsins is di¡erentially regulated by Ca2 [239]. In
case of some copines, calcium-dependent, phospho-
lipid-binding proteins, conserved from Paramecium
to humans [167] it has been shown that they bind
to an ATP a⁄nity column in a calcium-dependent
manner [240]. The function within the cell of many
proteins known to interact or bind Ca2 is still not
elucidated. Considering the ability of annexins to
bind Ca2 and ATP, and form ternary complexes
with phospholipid molecules it may be assumed
that they play a role of calcium bu¡ering or calcium
e¡ectors and serve as transducers of calcium signal.
Recently, the hydrolytic activity of annexin VII
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(synexin) towards GTP [241], and phosphodiesterase
activity inhibited by phospholipid binding, and my-
osin-like hydrolytic activity towards ATP of some
plant annexins [242,243] have been described. Since
GTP and its non-hydrolysable analog GTPQS are
known to promote the Ca2-dependent exocytosis
in many cell types by a mechanism thought to in-
volve as yet unknown proteins, Pollard and his co-
workers hypothesized that annexin VII may play the
role of one of such proteins [241]. They have used
streptolysin O-permeabilized cells and have found
that the initial rate of annexin VII-driven Ca2-de-
pendent aggregation of chroma⁄n granules and
phosphatidylserine liposomes is increased by
GTPQSsGTP, while 1 mM ATP, CTP, UTP,
GDP or GMP were without e¡ect [241]. GTP in£u-
enced also liposome fusion driven by annexin VII
without changing the apparent K1=2 for calcium.
These e¡ects were accompanied by speci¢c binding
of GTP to annexin VII, which was dependent on
Ca2 with two apparent K1=2 values for calcium
(0.25 and 2.5 mM). Moreover, annexin VII was
found to be able both in vitro and in vivo to hydro-
lyze GTP in a manner dependent on calcium (K1=2
50 WM) which could be substituted by Mg2 (K1=2
400 WM) or another divalent cation. Pollard and his
colleagues applied a G-protein-like molecular switch
model in which the annexin VII-GTP form was ac-
tive and revealed fusogenic activity, while upon
MgGTP hydrolysis the protein became inactivated;
however, it could be reactivated upon elevation of
intracellular Ca2 concentration to 50^200 WM
[241]. In the opinion of many investigators, annexin
VI is not an ATPase nor does its amino acid se-
quence contain any known consensus sites for
ATP/GTP binding [244]. Annexin VII might, there-
fore, resemble calexcitin, a signaling protein that
binds GTP, is activated by calcium, translocates to
the cell membrane after phosphorylation, where in-
hibits potassium channels and increases cellular ex-
citability [245].
Co-distribution of annexin VI and actin in secre-
tory ameloblasts and odontoblasts of rat incisor [246]
may suggest a close relationship between nucleotide-
binding proteins within a cell. The interaction of an-
nexin VI with F-actin and L-subunit of brain spectrin
in neurons [247], where ATP plays the role of an
important neurotransmitter, favors this interpreta-
tion [248]. In line with the described phenomena is
the observation that translocation of annexin VI
from plasma membrane to cytosol in alveolar macro-
phages under oxidative stress matches elevation of
intracellular Ca2 [249]. The rise in cytosol Ca2
concentration has been attributed to inhibition of
plasma membrane Ca2-ATPase by products of lipid
peroxidation, to mitochondrial dysfunction and also
to annexin VI. Changes in membrane structure to-
gether with the ATP depletion and the ability of
elevated level of oxidized glutathione to react with
protein cysteine residues to form mixed disul¢des,
may result in detachment of annexin from the mem-
brane and release of a substantial amount of calcium
ions [249]. Therefore, the oxidative stress-induced
changes in Ca2 concentration [250,251] can modu-
late the signal transduction for the respiratory burst
and many calcium-dependent processes (Fig. 6).
It is very likely that the interaction of annexin VI
with ATP play an important role in chondrocytes.
These cells take up calcium ions and accumulate
them in secretory vesicles, which are primary initia-
tors of extracellular mineral deposition in endochon-
drial calci¢cation [252]. These secretory vesicles bind
collagens II and X which stimulate accumulation of
Ca2 in these vesicles. Binding of collagens is modu-
lated by annexins II, V, and VI, expressed at a high
level in chondrocytes [253,254]. In addition, chondro-
cytes excrete ATP which, in turn, is involved in reg-
ulation of cell maturation and determines the
amount and type of mineral compounds produced
by these cells [255]. Moreover, matrix vesicles that
accumulate Ca2 during the initiation of mineraliza-
tion of growing bone, are rich in annexin V, and
evidence was provided that annexin V forms a multi-
conductance Ca2 channel in membranes of these
vesicles. Moreover, ATP and GTP were found to
di¡erentially modulate the activity of this channel:
ATP increased the amplitude of the current and the
number of conductance states, while GTP reduced
the number of events and of conductance states
[226].
The discovery of some annexin isoforms being in
vitro intracellular targets for ATP/GTP and other
nucleotides, such as cAMP, shed a new light on
some general functions of these isoforms in vivo.
Thus, annexins would represent an example among
the growing in number group of proteins for which
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nucleotides would play a role of important ligands
and not only be a source of metabolic energy. In
fact, even within the known families of proteins shar-
ing a common topology of macromolecules catalyz-
ing ATP-triggered reactions [6], there is a vast num-
ber of examples of ATP and other nucleotides
playing important structural roles. For example, the
cystic ¢brosis transmembrane conductance regulator
nucleotide binding folds may constitute a portion of
the ion-conducting channel [256]. The major goals of
further research should be to identify the region
within an annexin molecule responsible for nucleo-
tide binding [229] and ¢nd an answer to the question
whether binding of ATP/other nucleotides is respon-
sible for any conformational rearrangement within
the molecule which might have functional implica-
tions.
3. Concluding remarks
In addition to its well-established role in intracel-
lular metabolism [257], ATP has also an important
extracellular role propagated via purinergic P2 recep-
tors [9,11]. ATP serves as a fast neurotransmitter in a
variety of tissues and its postjunctional actions are
curtailed by dephosphorylation to adenosine by
membrane and soluble nucleotidases [258]. However,
a wealth of data and, particularly, recent observa-
tions on various ATP-dependent ion channels and
calcium- and phospholipid-binding proteins (such
as annexins), being ATP-binding molecules, have un-
ambiguously demonstrated that ATP and probably
other adenine nucleotides are ubiquitous intracellular
mediators involved in many essential biological proc-
esses. In fact, intracellular ATP levels are supposed
to be determinants for cell death modes, i.e. apopto-
sis or necrosis [259], and profound alterations in
ATP homeostasis have been reported in hypoxia
[260], under oxidative stress [261], and in other
pathological states, such as diabetes mellitus [262].
Changes in concentrations of free and bound ATP
have been also measured during intracellular Ca2
signaling [263], and, simultaneously, calcium concen-
trations were a¡ected by the level of ATP, as ob-
served in the case of proximal tubules where ATP
depletion caused an increase in cytosol Ca2 concen-
tration above 0.1 mM [264]. Changes in the concen-
tration of ATP seems to be characterized by slow
kinetics. ATP levels during cardiac ischemia drop
to 20% of their initial value after approximately 15
min [265]. A similar time scale for the lowering of the
intracellular ATP level was observed during cardiac
hypoxia and inhibition of glycolysis [266]. Spontane-
ous oscillations of glycolysis lead to oscillations of
the ATP/ADP ratio within minutes, resulting
amongst other e¡ects, in the opening and closing of
Fig. 6. The e¡ect of oxidative stress on intracellular localization
of the annexin molecules (Anx). Lipid peroxidation creates lipid
hydroperoxides and free radicals which a¡ect both membrane
permeability to calcium ions and calcium-dependent binding of
annexins to membranes, while oxygen radicals are deleterious
to various membrane and cytosolic proteins and also to nucleic
acids. Oxidative stress is accompanied by depletion in ATP and
reduced glutathione contents, inhibition (3) of plasma mem-
brane Ca2-ATPase, disturbances in mitochondrial Ca2 ho-
meostasis, and increase of intracellular content of oxidized glu-
tathione (GSSG). These changes lead to the detachment of
annexins from the membrane, and the overall increase of cyto-
solic calcium concentration. Annexins in cytosol are no longer
inhibitory to phospholipase A2 (PLA2) which, being activated
(+), causes further damage to the membrane lipid barrier. The
described changes lead to various cellular responses mediated
by calcium-dependent enzymes and proteins. Other explanations
are given in the text.
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the KATP channel [267]. Fast changes in free ATP
concentrations, in the millisecond range, take place
during intracellular calcium signaling and may have
some protective role for cells against excitatory cal-
cium signals and the unwanted energy consumption
required to maintain calcium movements and calci-
um-dependent processes [263,268]. However, even
long-time scale changes in cytosolic ATP concentra-
tions do not rule out ATP being an important and
e⁄cient metabolic messenger. Two factors have to be
taken into consideration in further studies of a mes-
senger role for ATP. First, its spatial distribution
within cells, and second, the kinetics of local changes
of ATP level.
The role of ATP as a ligand and not only as a
source of energy has been recently substantiated by
many observations coming from various laborato-
ries, concerning even the proteins well known to hy-
drolyze ATP. It has been also established that in the
case of actin, the binding of nucleotide regulates its
interaction with myosin [7,230] and protects F-actin
against heat and pressure denaturation [231]. In the
case of myosin, binding of nucleotide induces closure
of the ATP-binding pocket [233], and, thus plays an
important role in the catalytic cycle of the protein
[269]. Furthermore, ATP takes part in formation of
the higher a⁄nity binding site for caldesmon on
smooth muscle myosin molecules [270], and a¡ects
binding of actin to its accessory proteins such as
gelsolin [238]. On the other hand, ATP mediates dis-
sociation of the mitochondrial chaperone Hsp70 sys-
tem, a¡ecting its activity [271]. In other heat shock
proteins (Hsp90), the amino-terminal domain of the
protein has been suggested to play a role of an ATP/
ADP switch domain that regulates Hsp90 conforma-
tion [272]. Another function was described for the
nucleotide binding folds of cystic ¢brosis transmem-
brane conductance regulator, which form a portion
of the protein ion-conducting channel [256,273].
Moreover, many other proteins, in addition to ion
channels and annexins described in detail in the
present review, have been shown to interact with
ATP via the mechanism not involving ATP hydrol-
ysis, an outstanding example being mitochondrial
cytochrome c oxidase [18,274] and synapsins I and
II [239]. In the case of acetylcholine receptors, exog-
enous ATP stabilizes the degradation half-life time of
the receptor [275]. Recently, an adenine nucleotide
binding-site has been discovered in interferon-K2,
member of a group of related polypeptides that
play a major role in mediating the antiviral state,
the immune response, cell growth and di¡erentiation
[276].
Elucidation of the contribution of di¡erent proc-
esses to ATP regulation is a di⁄cult task, mainly
because of complex regulation of metabolic events
and ‘cross-talk’ between di¡erent processes. Studies
on ATP-binding proteins have largely contributed to
our knowledge of basic, vital cellular functions.
Analysis of protein structure resulted in discovery
of new chain folds in proteins that bind nucleotides
[4,5], and helped, by using these nucleotide-binding
folds as particular protein ‘¢nger prints’, to establish
the real function of many protein families
[6,8,277,278]. Better understanding of intracellular
ATP interaction with proteins could not only signi¢-
cantly deepen our knowledge of cellular physiology,
but also could be taken advantage of in treatment of
many diseases or pathologies, such as diabetes melli-
tus or cardiovascular diseases.
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